Intravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferation

Retina

Volumn 28, Issue 5, 2008, Pages 689-695

  Ghazi, Nicola G ^a,b   Knape, Robert M ^a   Kirk, Tyler Q ^a   Tiedeman, James S ^a   Conway, Brian P ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Age related macular degeneration; Bevacizumab (Avastin); Retinal angiomatous proliferation

Indexed keywords

BEVACIZUMAB;

AGED; ANATOMY; ARTICLE; CASE STUDY; CLINICAL ARTICLE; COMPARATIVE STUDY; EYE; EYE EXAMINATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INJECTION; INTERVENTION STUDY; MALE; OPHTHALMOLOGY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA LUTEA; RETINAL ANGIOMATOUS PROLIFERATION; RETROSPECTIVE STUDY; THERAPY EFFECT; THICKNESS; VISION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANGIOMATOSIS; ANTIBODIES, MONOCLONAL; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; MALE; RETINAL NEOVASCULARIZATION; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 43249127098     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318162d982     Document Type: Article

References (45)

1. Yannuzzi LA, Negrao S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina 2001;21:416-434.
2. Hartnett ME, Weiter JJ, Gardts A, Jalkh AE. Classification of retinal pigment epithelial detachments associated with drusen. Graefes Arch Clin Exp Ophthalmol 1992;230:11-19.
3. Kuhn D, Meunier I, Soubrane G, Coscas G. Imaging of chorioretinal anastomoses in vascularized retinal pigment epithelial detachments. Arch Ophthalmol 1995;113:1392-1398.
4. Gass JD, Agarwal A, Lavina AM, Tawansy KA. Focal inner retinal hemorrhages in patients with drusen: an early sign of occult choroidal neovascularization and chorioretinal anastomosis. Retina 2003;23:741-751.
5. Slakter JS, Yannuzzi LA, Schneider U, et al. Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration. Ophthalmology 2000;107:742-754.
6. Bottoni F, Massacesi A, Cigada M, et al. Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation. Arch Ophthalmol 2005;123:1644-1650.
7. Johnson TM, Glaser BM. Focal laser ablation of retinal angiomatous proliferation. Retina 2006;26:765-772.
8. Krieglstein TR, Kampik A, Ulbig M. Intravitreal triamcinolone and laser photocoagulation for retinal angiomatous proliferation. Br J Ophthalmol 2006;90:1357-1360.
9. Kusserow Michels S, Schmidt-Erfurth U. Chorioretinal anastomosis as unfavourable prognostic factor during photodynamic therapy. Ophthalmologe 2003;23:417-420.
10. Boscia F, Furino C, Sborgia L, et al. Photodynamic therapy for retinal angiomatous proliferations and pigment epithelium detachment. Am J Ophthalmol 2004;138:1077-1079.
11. Panagiotidis D, Karagiannis DA, Baltatzis S. Photodynamic therapy in retinal angiomatous proliferation stage I. Eur J Ophthalmol 2006;16:326-329.
12. Boscia F, Parodi MB, Furino C, et al. Photodynamic therapy with verteporfin for retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol 2006;244:1224-1232.
13. Gomez-Ulla F, Abraldes MJ, Fernandez M, Olmedo M. Successful treatment of retinal angiomatous proliferation by photodynamic therapy. Optom Vis Sci 2006;83:546-549.
14. Salazar-Diez JL, Iturralde-Errea D, Diaz-de-Durana-Santacoloma E, et al. Results of treatment of retinal angiomatous proliferation with photodynamic therapy. [Spanish] Arch Soc Esp Oftalmol 2006;81:401-404.
15. Criswell MH, Ciulla TA, Lowseth LA, et al. Anastomotic vessels remain viable after photodynamic therapy in primate models of choroidal neovascularization. Invest Ophthalmol Vis Sci 2005;46:2168-2174.
16. Kuroiwa S, Arai J, Gaun S, et al. Rapidly progressive scar formation after transpupillary thermotherapy in retinal angiomatous proliferation. Retina 2003;23:417-420.
17. Klais CM, Eandi CM, Ober MD, et al. Anecortave acetate treatment for retinal angiomatous proliferation: a pilot study. Retina 2006;26:773-779.
18. Sakimoto S, Gomi F, Sakaguchi H, Tano Y. Recurrent retinal angiomatous proliferation after surgical ablation. Am J Ophthalmol 2005;139:917-918.
19. Borrillo JL, Sivalingam A, Martidis A, Federman JL. Surgical ablation of retinal angiomatous proliferation. Arch Ophthalmol 2003;121:558-561.
20. Lafaut BA, Aisenbrey S, Broecke CV, Bartz-Schmidt KU. Clinicopathological correlation of deep retinal vascular anomalous complex in AMD. Br J Ophthalmol 2000;84:1269-1274.
21. Nicolo M, Ghiglione D, Lai S, Calabria G. Retinal angiomatous proliferation treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol 2006;244:1336-1338.
22. Bottoni F, Romano M, Massacesi A, Bergamini F. Remodeling of the vascular channels in retinal angiomatous proliferations treated with intravitreal triamcinolone acetonide and photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 2006;244:1528-1533.
23. Sutter FK, Kurz-Levin MM, Fleischhauer J, et al. Macular atrophy after combined intravitreal triamcinolone acetonide (IVTA) and photodynamic therapy (PDT) for retinal angiomatous proliferation (RAP). Klin Monatsbl Augenheilkd 2006;223:376-378.
24. Boscia F, Furino C, Prascina F, et al. Combined surgical ablation and intravitreal triamcinolone acetonide for retinal angiomatous proliferation. Eur J Ophthalmol 2005;15:513-516.
25. Nakata M, Yuzawa M, Kawamura A, Shimada H. Combining surgical ablation of retinal inflow and outflow vessels with photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol 2006;141:968-970.
26. Freund KB, Klais CM, Eandi CM, et al. Sequenced combined intravitreal triamcinolone and indocyanine green angiography-guided photodynamic therapy for retinal angiomatous proliferation. Arch Ophthalmol 2006;124:487-492.
27. Meyerle CB, Freund KB, Iturralde D, et al. Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation. Retina 2007;27:451-457.
28. Gross NE, Aizman A, Brucker A, et al. Nature and risk of neovascularization in the fellow eye of patients with unilateral RAP. Retina 2005;25:713-718.
29. Gragoudas ES, Adamis AP, Cunningham ET, et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
30. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
31. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
32. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
33. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-1047.
34. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization promises and potential problems. JAMA 2005;293:1509-1513.
35. Bakri SJ, Cameron JD, McCannel CA, et al. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 2006;142:162-164.
36. Luthra S, Narayanan R, Marques LE, et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 2006;26:512-518.
37. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006;26:262-269.
38. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006;26:257-261.
39. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372.
40. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:270-274.
41. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-390.
42. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
43. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:1-9.
44. Yamamoto I, Rogers AH, Reichel E, et al. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathologic myopia. Br J Ophthalmol 2007;91:157-160.
45. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the Internet to assess drug safety worldwide. Br J Ophthalmol. Available at: http://bjo.bmjjournals.com/cgi/rapidpdf/bjo.2006. 099598v1. Accessed July 19, 2006.